Causality Assessment in Drug-Induced Liver Injury

被引：40
作者：
Hayashi, Paul H. [1 ]
机构：
[1] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, UNC Liver Program, Chapel Hill, NC 27599 USA
来源：
SEMINARS IN LIVER DISEASE | 2009年 / 29卷 / 04期
关键词：
Hepatotoxicity; dietary supplements; expert opinion; adverse drug reactions; ADVERSE-REACTIONS; CONSENSUS MEETINGS; PROBABILITY; AGREEMENT; SCALE; HYPERSENSITIVITY; ASSOCIATION; VALIDATION; DIAGNOSIS; CRITERIA;
D O I：
10.1055/s-0029-1240003
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Assigning causality in drug-induced liver injury (DILI) due to a particular medication or herbal and dietary supplement relies on clinical history, exclusion of competing causes, prior reports of DILI, and judgment-no objective laboratory or histological tests exist to confirm a diagnosis of suspected DILI. Current causality assessment instruments are based on algorithmic scoring systems but are not widely used. Expert opinion remains the gold standard, but is cumbersome and has limited reproducibility. The lack of a valid and widely available causality assessment method hinders the identification of genetic and biochemical markers that may help better define DILI. Emerging technologies in pharmacogenomics and toxicogenomics may identify such markers if well-defined DILI cases and controls can provide tissue samples for analysis. In this article, current causality assessment instruments, including expert opinion, are discussed, and the necessary features for an improved instrument are provided.
引用
收藏
页码：348 / 356
页数：9
相关论文
共 42 条
[21]   Developmental pharmacology - Drug disposition, action, and therapy in infants and children [J].
Kearns, GL ;
Abdel-Rahman, SM ;
Alander, SW ;
Blowey, DL ;
Leeder, JS ;
Kauffman, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (12) :1157-1167
[22]  
Klemer D, 2007, GASTROENTEROLOGY, V132, pA773
[23]   ALGORITHM FOR THE OPERATIONAL ASSESSMENT OF ADVERSE DRUG-REACTIONS .1. BACKGROUND, DESCRIPTION, AND INSTRUCTIONS FOR USE [J].
KRAMER, MS ;
LEVENTHAL, JM ;
HUTCHINSON, TA ;
FEINSTEIN, AR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1979, 242 (07) :623-632
[24]   Timing of new black box warnings and withdrawals for prescription medications [J].
Lasser, KE ;
Allen, PD ;
Woolhandler, SJ ;
Himmelstein, DU ;
Wolfe, SN ;
Bor, DH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (17) :2215-2220
[25]   Acute liver failure: Summary of a workshop [J].
Lee, William M. ;
Squires, Robert H., Jr. ;
Nyberg, Scott L. ;
Doo, Edward ;
Hoofnagle, Jay H. .
HEPATOLOGY, 2008, 47 (04) :1401-1415
[26]   Assessment of drug-induced liver injury in clinical practice [J].
Lucena, M. Isabel ;
Garcia-Cortes, Miren ;
Cueto, Raquel ;
Lopez-Duran, J. L. ;
Andrade, Raul J. .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 (02) :141-158
[27]   Comparison of two clinical scales for causality assessment in hepatotoxicity [J].
Lucena, MA ;
Camargo, R ;
Andrade, RJ ;
Perez-Sanchez, CJ ;
De la Cuesta, FS .
HEPATOLOGY, 2001, 33 (01) :123-130
[28]   Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].
Mallal, S ;
Nolan, D ;
Witt, C ;
Masel, G ;
Martin, AM ;
Moore, C ;
Sayer, D ;
Castley, A ;
Mamotte, C ;
Maxwell, D ;
James, I ;
Christiansen, FT .
LANCET, 2002, 359 (9308) :727-732
[29]  
Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319
[30]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
12345